LiveFollow-On

NovaPharma Follow-On Offering

NovaPharma is raising £10M through a follow-on offering to fund Phase III clinical trials for its breakthrough oncology treatment NP-401.

Investing involves risk. The value of your investment can fall as well as rise and you may get back less than you invest. Any decision to invest should be based on the information in the relevant prospectus or offering document. RetailBook does not provide investment advice.

Key Metrics

£10M
Target Raise: £1,000.00
Min Investment: Expected at a discount to the reference price
Price Guidance: 20 Feb 2026
Closes

GBP
Currency

Story

The Story

NovaPharma plc is a clinical-stage biopharmaceutical company focused on next-generation treatments for solid tumour cancers. Since listing on the London Stock Exchange in 2022, the company has developed a pipeline of three oncology candidates.

The Opportunity

This follow-on raise will fund Phase III trials for NP-401 in non-small cell lung cancer (NSCLC). Earlier-stage results showed a statistically significant progression-free survival benefit versus standard care with a favourable safety profile.

Why This Matters

Large Addressable Market: Global NSCLC therapeutics is a multi-billion-dollar market with continuing growth.
Commercial Pathway: A conditional licensing arrangement with a top-5 pharmaceutical partner supports global commercialisation planning.
Clear Use of Proceeds: Capital is directly linked to a late-stage clinical milestone with defined regulatory objectives.

Important: Clinical-stage biotech investments carry elevated risk, including trial, regulatory, and funding risk. Capital at risk.

Investment Highlights

Breakthrough Clinical Results

Key point: Phase II trials showed 42% improvement in progression-free survival for NSCLC patients, with p<0.001 statistical significance.

Large Addressable Market

Key point: The global NSCLC therapeutics market exceeds $25 billion annually, with NP-401 targeting a segment where existing treatments have limited efficacy.

Commercial Partnership Secured

Key point: Conditional licensing deal with a top-5 pharma company provides up to £200M in milestone payments plus royalties, significantly de-risking commercialisation.

Financials & Specifications

Follow-On Type: TBD
Shareholders Only: No
Reference Price: TBD
Ticker: NVPH
ISIN: GB00B5551234

Risk Factors

Phase III trials may not replicate Phase II results. Failure to demonstrate efficacy or safety could result in a complete loss of R&D investment.

Clinical Trial Risk

Phase III trials may not replicate Phase II results. Failure to demonstrate efficacy or safety could result in a complete loss of R&D investment.

Regulatory Approval Uncertainty

There is no guarantee that NP-401 will receive marketing authorisation from the MHRA, EMA, or FDA even if clinical trials are successful.

Dilution Risk

This follow-on offering will dilute existing shareholders by approximately 12%. Further capital raises may be required if Phase III costs exceed projections.

Cash Runway

NovaPharma is pre-revenue and cash-burning. If the follow-on raise is undersubscribed, the company may need to seek alternative funding on less favourable terms.

Competitive Pipeline

Several competitors have NSCLC candidates in late-stage trials. First-to-market advantage cannot be guaranteed.

Manufacturing Scale-Up

Transition from clinical-scale to commercial-scale manufacturing involves significant technical and regulatory hurdles that could delay market launch.

How to Participate

Select a Broker

Choose from our trusted broker partners

Review Documents

Read the prospectus and key information

Place Your Order

Submit your investment through your chosen broker

Allocation

Receive your allocation notification

Settlement

Shares settled and delivered to your account

Education

What is a Follow-On Offering?

A follow-on offering is when a company that is already publicly listed issues additional shares. This can raise capital for growth, acquisitions, or debt repayment.

Understanding dilution

When new shares are issued, existing shareholders' ownership percentage decreases — this is called dilution. The impact depends on the number of new shares relative to existing shares.

Pricing dynamics

Follow-on shares are typically priced at a discount to the current market price to attract investors. The discount and demand determine the final pricing.

Offer Timeline

Announcement
5 Feb 2026
Book Build
10 Feb 2026
Applications Open
13 Feb 2026
Applications Close
20 Feb 2026
Allocation
TBD
Settlement
TBD
Admission
27 Feb 2026
Lockup Expiry
16 May 2026

Capital at risk. Investing in clinical-stage pharmaceutical companies carries significant risk. The value of your investment can go down as well as up and you could lose your entire investment. Past performance and clinical trial results are not reliable indicators of future outcomes. This financial promotion is approved by RetailBook Capital Limited (FCA FRN: 123456).

Loading offer details

Preparing the full offer view...

Key Metrics

£10M
Target Raise: £1,000.00
Min Investment: Expected at a discount to the reference price
Price Guidance: 20 Feb 2026
Closes

GBP
Currency

Story

The Story

The Opportunity

Why This Matters

Large Addressable Market: Global NSCLC therapeutics is a multi-billion-dollar market with continuing growth.
Commercial Pathway: A conditional licensing arrangement with a top-5 pharmaceutical partner supports global commercialisation planning.
Clear Use of Proceeds: Capital is directly linked to a late-stage clinical milestone with defined regulatory objectives.

Important: Clinical-stage biotech investments carry elevated risk, including trial, regulatory, and funding risk. Capital at risk.

Investment Highlights

Breakthrough Clinical Results

Key point: Phase II trials showed 42% improvement in progression-free survival for NSCLC patients, with p<0.001 statistical significance.

Large Addressable Market

Key point: The global NSCLC therapeutics market exceeds $25 billion annually, with NP-401 targeting a segment where existing treatments have limited efficacy.

Commercial Partnership Secured

Key point: Conditional licensing deal with a top-5 pharma company provides up to £200M in milestone payments plus royalties, significantly de-risking commercialisation.

Financials & Specifications

Follow-On Type: TBD
Shareholders Only: No
Reference Price: TBD
Ticker: NVPH
ISIN: GB00B5551234

Risk Factors

Phase III trials may not replicate Phase II results. Failure to demonstrate efficacy or safety could result in a complete loss of R&D investment.

Clinical Trial Risk

Phase III trials may not replicate Phase II results. Failure to demonstrate efficacy or safety could result in a complete loss of R&D investment.

Regulatory Approval Uncertainty

There is no guarantee that NP-401 will receive marketing authorisation from the MHRA, EMA, or FDA even if clinical trials are successful.

Dilution Risk

This follow-on offering will dilute existing shareholders by approximately 12%. Further capital raises may be required if Phase III costs exceed projections.

Cash Runway

NovaPharma is pre-revenue and cash-burning. If the follow-on raise is undersubscribed, the company may need to seek alternative funding on less favourable terms.

Competitive Pipeline

Several competitors have NSCLC candidates in late-stage trials. First-to-market advantage cannot be guaranteed.

Manufacturing Scale-Up

Transition from clinical-scale to commercial-scale manufacturing involves significant technical and regulatory hurdles that could delay market launch.

How to Participate

Select a Broker

Choose from our trusted broker partners

Review Documents

Read the prospectus and key information

Place Your Order

Submit your investment through your chosen broker

Allocation

Receive your allocation notification

Settlement

Shares settled and delivered to your account

Education

What is a Follow-On Offering?

A follow-on offering is when a company that is already publicly listed issues additional shares. This can raise capital for growth, acquisitions, or debt repayment.

Understanding dilution

When new shares are issued, existing shareholders' ownership percentage decreases — this is called dilution. The impact depends on the number of new shares relative to existing shares.

Pricing dynamics

Follow-on shares are typically priced at a discount to the current market price to attract investors. The discount and demand determine the final pricing.

Offer Timeline

Announcement
5 Feb 2026
Book Build
10 Feb 2026
Applications Open
13 Feb 2026
Applications Close
20 Feb 2026
Allocation
TBD
Settlement
TBD
Admission
27 Feb 2026
Lockup Expiry
16 May 2026